Evidence-Based Clinical Practices on Shared Decision Making in Metastatic Breast Cancer
Release Date: May 1, 2017
Expiration Date: April 30, 2018
ESTIMATED TIME TO COMPLETE ACTIVITY:
Oncology experts provide current evidence based treatment guidelines and updates on emerging therapies for care of women with metastatic breast cancer (MBC). This CME activity is for medical oncologists, pathologists, physician assistants, nurse practitioners, oncology nurses, nurse navigators/social workers, palliative/symptom management teams who care for patients with HER2-positive MBC and quality administrators responsible for their cancer center’s adherence to value-based care delivery models.
The target audiences for these activities are medical oncologists, pathologists, physician assistants, nurse practitioners, oncology nurses, nurse navigators/social workers, palliative/symptom management teams who care for patients with HER2-positive MBC and quality administrators responsible for their cancer center’s adherence to value-based care delivery models. We will target centers participating in Centers for Medicare and Medicaid Services Oncology Care Model.
At the conclusion of these educational initiatives, participants should be able to:
Carlos Arteaga, MD
- Develop evidence-based treatment approaches for patients diagnosed with HER2-positive breast cancer in the metastatic setting
Rachel Freedman, MD, MPH
- Consider fit/frailty status when contemplating evidenced-based treatment options for older patients with HER2+ MBC
Joanne Buzaglo, PhD
- Define clinician and patient perceived indicators of effective SDM for HER2-positive metastatic breast cancer
- Evaluate the clinician and patient perceived feasibility/ satisfaction regarding using personalized treatment care plans to support shared decision making for HER2-positive metastatic breast cancer
Rachel Freedman, MD, MPH
Harvard Medical School
Carlos Arteaga, MD
Vanderbilt-Ingram Cancer Center
Joanne Buzaglo, PhD
Cancer Support Community
PHYSICIAN CONTINUING MEDICAL EDUCATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Carevive Systems, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™ (0.5 per module). Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING MEDICAL EDUCATION
This educational activity for 1.5 contact hours (0.5 per module) is provided by Postgraduate Institute for Medicine. Designated for 0.6 contact hours (0.2 per module) of pharmacotherapy credit for Advance Practice Registered Nurses.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related material that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Rachel Freedman, MD, MPH, has no real or apparent con conflicts of interest to report.
- Carlos Arteaga, MD; Consulting Fees, Astrazeneca, Bayer, Clovis, Kiyatek, LabCorp, Lilly, Merrimack, Novartis, Provista, Radius, Roche, Symphogen; Contracted Research, Novartis, PUMA Biotechnology, Symphogen; Ownership Interest, Provista.
- Joanne Buzaglo, PhD, has no real or apparent conflicts of interest to report.
The planners and managers reported the following nancial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following PIM planners and managers, Judi Smelker- Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, MSN, RN, CCMEP, hereby state that they or their spouse/life partner do not have any nancial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following Carevive Systems, Inc. planners and managers reported the following: Timothy J. DiChiara, PhD, Consulting Fees, Daiichi Sankyo, Inc.
METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CNE credit for this activity.
During the period May 1, 2017 through April 30, 2018 participants must read the learning objectives and faculty disclosures and study the educational activity.
To begin your participation in this CME/CNE activity, please take the pretest by accessing the following link: https://www.research.net/r/CR8SFNT
If you wish to receive acknowledgment for completing this activity, please complete the posttest and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 11892. Upon registering and successfully completing the posttest with a score of 50% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.
HARDWARE AND SOFTWARE REQUIREMENTS
CME University requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/ or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the of cial prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by Postgraduate Institute for Medicine and Carevive Systems, Inc.
This activity is supported by an independent educational grant from Genentech BioOncology. Activity ID: G-413